Alto Neuroscience, Inc. (NYSE:ANRO) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Alto Neuroscience, Inc. (NYSE:ANRO) have received a consensus rating of “Moderate Buy” from the ten ratings firms that are currently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have assigned a buy rating to the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $35.25.

Several research analysts have issued reports on ANRO shares. Bank of America initiated coverage on shares of Alto Neuroscience in a report on Tuesday, May 5th. They set a “buy” rating and a $35.00 price target for the company. Wolfe Research began coverage on shares of Alto Neuroscience in a research report on Friday, May 22nd. They set an “outperform” rating for the company. Weiss Ratings raised shares of Alto Neuroscience from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, May 1st. Robert W. Baird dropped their target price on shares of Alto Neuroscience from $38.00 to $36.00 and set an “outperform” rating on the stock in a report on Monday, May 18th. Finally, Chardan Capital reaffirmed a “buy” rating and set a $30.00 price target on shares of Alto Neuroscience in a research report on Wednesday, April 22nd.

Institutional Investors Weigh In On Alto Neuroscience

Several institutional investors and hedge funds have recently made changes to their positions in the business. Northwestern Mutual Wealth Management Co. boosted its holdings in shares of Alto Neuroscience by 14,567.0% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 212,672 shares of the company’s stock worth $3,786,000 after buying an additional 211,222 shares in the last quarter. Artia Global Partners LP bought a new stake in shares of Alto Neuroscience in the 4th quarter valued at $520,000. Perceptive Advisors LLC lifted its position in shares of Alto Neuroscience by 1,048.5% during the 4th quarter. Perceptive Advisors LLC now owns 1,784,393 shares of the company’s stock valued at $31,762,000 after acquiring an additional 1,629,027 shares during the period. 683 Capital Management LLC bought a new position in Alto Neuroscience during the fourth quarter worth $1,153,000. Finally, Commodore Capital LP bought a new position in Alto Neuroscience during the fourth quarter worth $32,453,000.

Alto Neuroscience Price Performance

Shares of ANRO opened at $25.95 on Thursday. Alto Neuroscience has a 1 year low of $2.50 and a 1 year high of $28.44. The company has a debt-to-equity ratio of 0.07, a current ratio of 20.52 and a quick ratio of 20.52. The company has a market capitalization of $910.59 million, a price-to-earnings ratio of -10.72 and a beta of 1.04. The business has a 50-day moving average of $22.76 and a 200-day moving average of $20.80.

Alto Neuroscience (NYSE:ANRO) last posted its quarterly earnings data on Wednesday, May 13th. The company reported ($0.80) EPS for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.24). As a group, equities research analysts anticipate that Alto Neuroscience will post -3.01 earnings per share for the current year.

About Alto Neuroscience

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.